24 Roy Street
Seattle, WA 98109
Complete this contact form for media, investor relations and partnership/business development inquiries
Please leave this field empty.
* required fields
A Feasibility Study of the EMulate Therapeutics Voyager System in Patients with Recurrent Glioblastoma Multiforme (rGBM). This study is currently recruiting qualified patients.
Abstract presented by Xavier Figueroa, PhD, at Society for Neuro-Oncology 2016 Annual Conference, Scottsdale, AZ on November 19, 2016.
The latest information on publications highlighting EMulate Therapeutics research and advancements.
November 14, 2019
EMulate® Therapeutics Announces Multiple Presentations on the Voyager and Hælo® systems
October 17, 2019
EMulate Therapeutics® Inks Distribution Agreement for India with Sayre Therapeutics
August 28, 2019
EMulate Therapeutics® Submits Application for CE Mark
EMulate Therapeutics Voyager® ulRFE® System for rGBM is an investigational medical device. Limited by United States law to investigational use only.
© EMulate Therapeutics 2020. All rights reserved.